ARTELO BIOSCIENCES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ARTELO BIOSCIENCES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.88M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($9.83M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($9.29M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($10.08M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($4.04M) | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | ($7.44M) | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | ($4.66M) | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | ($2.17M) | Nov 4, 2020 |
| FY2019 | Aug 31, 2018 | ($2.34M) | Dec 18, 2019 |
| FY2018 | Aug 31, 2017 | ($234.9K) | Nov 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.40M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($10.11M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($9.93M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($10.29M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($4.04M) | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | ($7.44M) | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | ($4.69M) | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | ($3.21M) | Nov 4, 2020 |
| FY2019 | Aug 31, 2018 | ($2.34M) | Dec 18, 2019 |
| FY2018 | Aug 31, 2017 | ($232.8K) | Nov 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.42M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $5.99M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.70M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $4.32M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.94M | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | $2.84M | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | $1.92M | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | $1.09M | Nov 4, 2020 |
| FY2019 | Aug 31, 2018 | $1.25M | Dec 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.52M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($8.35M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($8.21M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($8.01M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($2.67M) | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | ($6.14M) | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | ($4.35M) | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | ($2.79M) | Nov 4, 2020 |
| FY2019 | Aug 31, 2018 | ($1.61M) | Dec 18, 2019 |
| FY2018 | Aug 31, 2017 | ($216.8K) | Nov 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.70M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $13.04M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $20.42M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $28.25M | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | $12.64M | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | $4.38M | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | $6.48M | Nov 4, 2020 |
| FY2019 | Aug 31, 2018 | $397.0K | Dec 18, 2019 |
| FY2018 | Aug 31, 2017 | $574.3K | Nov 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.07M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.84M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.29M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.02M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.08M | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | $593.0K | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | $501.0K | Nov 29, 2021 |
| FY2016 | Aug 31, 2016 | $17.4K | Nov 29, 2016 |
| FY2016 | Aug 31, 2015 | $1.7K | Nov 29, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.27M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.86M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $11.75M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $19.40M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $27.17M | Mar 25, 2024 |
| FY2022 | Aug 31, 2021 | $12.04M | Mar 31, 2023 |
| FY2022 | Aug 31, 2020 | $3.88M | Mar 31, 2023 |
| FY2021 | Aug 31, 2019 | $5.46M | Nov 29, 2021 |
| FY2020 | Aug 31, 2018 | ($135.0K) | Nov 4, 2020 |
| FY2019 | Aug 31, 2017 | $544.8K | Dec 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($63.02M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($50.14M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($40.31M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($31.02M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($20.94M) | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | ($16.90M) | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | ($9.47M) | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | ($4.81M) | Nov 4, 2020 |
| FY2019 | Aug 31, 2018 | ($2.64M) | Dec 18, 2019 |
| FY2018 | Aug 31, 2017 | ($295.1K) | Nov 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $600.0K | Feb 24, 2026 |
| FY2022 | Dec 31, 2022 | $6.89M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $12.16M | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | $6.63M | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | $2.14M | Nov 29, 2021 |
| FY2021 | Aug 31, 2019 | $4.42M | Nov 29, 2021 |
| FY2020 | Aug 31, 2018 | $337.4K | Nov 4, 2020 |
| FY2019 | Aug 31, 2017 | $572.8K | Dec 18, 2019 |
| FY2018 | Aug 31, 2016 | $3.6K | Nov 29, 2018 |
| FY2017 | Aug 31, 2015 | $17.0K | Nov 29, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Aug 31, 2019 | (1) | Dec 18, 2019 |
| FY2019 | Aug 31, 2018 | (1) | Dec 18, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (12) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | (18) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 3, 2025 |
| FY2019 | Aug 31, 2019 | (1) | Dec 18, 2019 |
| FY2019 | Aug 31, 2018 | (1) | Dec 18, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.02M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 567,582 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 3.19M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 2.86M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 2.82M | Mar 31, 2023 |
| FY2022 | Aug 31, 2021 | 1.64M | Mar 31, 2023 |
| FY2021 | Aug 31, 2020 | 4.99M | Nov 29, 2021 |
| FY2020 | Aug 31, 2019 | 3.35M | Nov 4, 2020 |
| FY2019 | Aug 31, 2018 | 1.75M | Dec 18, 2019 |
| FY2018 | Aug 31, 2017 | 11.33M | Nov 29, 2018 |